Indaptus Therapeutics (INDP) Change in Accured Expenses (2020 - 2026)

Indaptus Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 585.47% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$6.8 million (down 412.52% YoY), while the FY2023 annual figure was -$680520.0, up 41.07% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.2 million, down from -$762338.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $570763.0 in Q4 2022, with the low at -$5.2 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is -$743950.0 (2022), against an average of -$823705.6.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses jumped 596.12% in 2023, then sank 585.47% in 2026.
• Indaptus Therapeutics' Change in Accured Expenses stood at $570763.0 in 2022, then decreased by 28.47% to $408265.0 in 2023, then slumped by 403.11% to -$1.2 million in 2024, then jumped by 38.4% to -$762338.0 in 2025, then tumbled by 585.47% to -$5.2 million in 2026.
• Business Quant data shows INDP's Change in Accured Expenses at -$5.2 million in Q1 2026, -$762338.0 in Q1 2025, and -$1.2 million in Q1 2024.